U.S. Markets closed

Market Has Not Yet Noticed Potential in Akebia Therapeutics (AKBA); Have You?

Zacks Equity Research

It commonly happens in stock investing that investors miss the chance of buying winning stocks that they knew would stand out. Before they take the plunge, others get to know the hidden potential and enter into these stocks, pushing them out of reach.

So, instead of repenting, spotting the off-the-radar potential winners and immediately investing in them could be a smart decision.

One such company that looks well positioned for a solid gain, but has been overlooked by investors lately, is Akebia Therapeutics, Inc. AKBA. This Medical – Drugs stock has actually seen estimates rise over the past month for the current fiscal year by about 17.9%. But that is not yet reflected in its price, as the stock gained only 2.9% over the same time frame.

Akebia Therapeutics, Inc. Price and Consensus

Akebia Therapeutics, Inc. Price and Consensus | Akebia Therapeutics, Inc. Quote

You should not be concerned about the price remaining muted going forward. This year’s expected earnings growth over the prior year is 37.6%, which should ultimately translate into price appreciation.

And if this isn’t enough, AKBA currently carries a Zacks Rank #2 (Buy) which further underscores the potential for its outperformance (See the performance of Zacks' portfolios and strategies here: About Zacks Performance).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

So if you are looking for a stock flying under-the-radar that is well-equipped to bounce down the road, make sure to consider Akebia Therapeutics. Solid estimate revisions and an impressive Zacks Rank suggest that better days may be ahead for AKBA and that now might be an interesting buying opportunity.

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Akebia Therapeutics, Inc. (AKBA) : Free Stock Analysis Report
To read this article on Zacks.com click here.